Skip to content

Mylan launches HIV med in India

August 10, 2017

Mylan Pharmaceuticals Pvt Ltd, a subsidiary of Mylan N.V. has received marketing authorisation from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza.

Avonza ((TLE400) is a fixed-dose combination comprised of Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate tablets recommended by the World Health Organization (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS.

Commenting on the launch, Mylan President Rajiv Malik said: “Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs. Mylan is the first to offer this combination in India.’’

In April 2017, the Health Ministry in India launched the Test and Treat Policy for HIV; anyone testing positive for HIV would get antiretroviral therapy irrespective of the CD4 count or clinical stage.

Globally, Mylan supplies life-saving ARVs to nearly 50 per cent of patients being treated for HIV/AIDS in more than 100 developing countries. Its ARV portfolio includes 14 active pharmaceutical ingredients and 50 finished dosage forms in first-line, second-line and paediatric formulations.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: